Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis

References

• Urological Infections. European Association of Urology. [ cited 2020 Jan 16]. Open access. Available from http://uroweb.org/guideline/urological-infections/
   Google Scholar
• Peterson J, Kaul S, Khashab M, et al. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther. 2007;29:2215.
   PubMed Web of Science ®Google Scholar
• Geerlings SE, Van Nieuwkoop C, Van Haarst E, et al. SWAB guidelines for antimicrobial therapy of complicated urinary tract infections in adults. SWAB Guidelines. 2013. Available from https://swab.nl/swab/cms3.nsf/uploads/41949F6BD9ED10EDC1257B7F00212560/$FILE/revised%20uti%20guideline%20FINAL%20010413.pdf
   Google Scholar
• Jones RN, Fritsche TR, Sader HS, et al. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn Microbiol Infect Dis. 2007;58(1):9–17.
   PubMed Web of Science ®Google Scholar
• Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PROTEKT US study. J Antimicrob Chemother. 2004;54(Suppl. 1):i7–15.
   PubMed Web of Science ®Google Scholar
• Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63(24):2769–2802.
   PubMed Web of Science ®Google Scholar
• Levaquin® (levofloxacin tablets, oral solution, injection): US prescribing information. Raritan (NJ): Ortho-McNeil Pharmaceutical, Inc.; 2008 Jan
   Google Scholar
• Hurst M, Lamb HM, Scott LJ, et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs. 2002;62(14):2127–2167.
   PubMed Web of Science ®Google Scholar
• Huband MD, Cohen MA, Zurack M, et al. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother. 2007;51(4):1191–1201.
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Jones RN. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999–2004). Diagn Microbiol Infect Dis. 2007;58(1):19–26.
   PubMed Web of Science ®Google Scholar
• Chow AT, Fowler C, Williams RR, et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 2001;45(7):2122–2125.
   PubMed Web of Science ®Google Scholar
• Chien SC, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1998;42(4):885–888.
   PubMed Web of Science ®Google Scholar
• Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 6, 2016.
   PubMedGoogle Scholar
• Tateda K, Ohno A, Ishii Y, et al. Levofloxacin surveillance group. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2016. J Infect Chemother. 2019;25(8):594–604.
   Web of Science ®Google Scholar
• Bouchillon SK, Badal RE, Hoban DJ, et al. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009–2011. Clin Ther. 2013;35(6):872–877.
   PubMed Web of Science ®Google Scholar
• Bosch-Nicolau P, Falcó V, Viñado B. A cohort study of risk factors that influence empirical treatment of patients with acute pyelonephritis. Antimicrob Agents Chemother. 2017;61(12). pii:e01317–17.
   PubMed Web of Science ®Google Scholar
• Bischoff S, Walter T, Gerigk M. Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department BMC Infect Dis. 2018;18:56.
   PubMed Web of Science ®Google Scholar
• Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:625.
   PubMed Web of Science ®Google Scholar
• Reyner K, Heffner AC, Karvetski CH, et al. Urinary obstruction is an important complicating factor in patients with septic shock due to urinary infection. Am J Emerg Med. 2016;34:694.
   PubMed Web of Science ®Google Scholar
• Pallett A, Hand KJ. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. Antimicrob Chemother. 2010;65(Suppl3): iii25–33.
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe – annual report of the European Antimicrobial Resistance Surveillance Network (EARS-net) 2017. Stockholm: ECDC; 2018.
   Google Scholar
• Gomila A, Carratalà J, Eliakim-Raz N, et al. Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study. Infect Drug Resist. 2018;11:2571–2581.
   PubMed Web of Science ®Google Scholar
• Klevens RM, Edwards JR, Gaynes RP. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. National nosocomial infections surveillance system. Clin Infect Dis. 2008;47(7):927–930.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009. Infect Control Hosp Epidemiol. 2013;34(9):940–946.
   PubMed Web of Science ®Google Scholar
• Rafat C, Debrix I, Hertig A. Levofloxacin for the treatment of pyelonephritis. Expert Opin Pharmacother. 2013;14(9):1241–1253.
   PubMed Web of Science ®Google Scholar
• Czaja CA, Scholes D, Hooton TM, et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007;45:273–280.
   PubMed Web of Science ®Google Scholar
• Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2010;122(6):7–15.
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton TM, Naber KG, et al. (Infectious Diseases Society of America., European Society for Microbiology and Infectious Diseases). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the iNfectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.
   PubMed Web of Science ®Google Scholar
• Prabhu A, Taylor P, Konecny P, et al. Pyelonephritis: what are the present day causative organisms and antibiotic susceptibilities? Nephrology. 2013;18:463–467.
   PubMed Web of Science ®Google Scholar
• Paterson DL. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Infect Control. 2006;34:20–28.
   Web of Science ®Google Scholar
• van der Starre WE, van Nieuwkoop C, Paltansing S, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. 2011;66:650.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385(9981):1949–1956.
   PubMed Web of Science ®Google Scholar
• Ren H, Li X, Ni Z-H, et al. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Int Urol Nephrol. 2017;49(3):499–507.
   PubMed Web of Science ®Google Scholar
• Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750mg once-daily for 5 days with ciprofloxacin 400/500mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71:17–22.
   PubMed Web of Science ®Google Scholar
• Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. In press.
   Web of Science ®Google Scholar
• US Food and Drug Administration. FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections 2016. cited 2018 Jun 26.
   Google Scholar
• Kabbani S, Hersh AL, Shapiro DJ, et al. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. Clin Infect Dis. 2018;67:134–136.
   PubMed Web of Science ®Google Scholar
• Fluoroquinolone and quinolone antibiotics: PRAC recommends restrictions on use. 5 October 2018 EMA/668915/2018.
   Google Scholar
• Hurst M, Lamb HM, Scott LJ, et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs. 2002;62(14):2127–2167.
   PubMed Web of Science ®Google Scholar
• Tandogdu Z, Cek M, Wagenlehner F, et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol. 2014;32:791–801.
   PubMed Web of Science ®Google Scholar
• Surveillance Report. European Centre for Disease Prevention and Control. [ cited 2020 Jan 16]. Available from https://ecdc.europa.eu/sites/portal/files/documents/EARS-Net-report-2017-update-jan-2019.pdf
   Google Scholar
• Zurfluh K, Abgottspon H, Hächler H, et al. Quinolone resistance mechanisms among extended-spectrum beta-lactamase (ESBL) producing Escherichia coli isolated from rivers and lakes in Switzerland. PLoS One. 2014;9(4):e95864.
   PubMed Web of Science ®Google Scholar
• de Lastours V, Chau F, Roy C, et al. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone. J Antimicrob Chemother. 2014;69:3393–3400.
   PubMed Web of Science ®Google Scholar
• Isendahl J, Giske CG, Tegmark Wisell K, et al. Risk factors for community-onset bloodstream infection with extended-spectrum β-lactamase-producing Enterobacteriaceae: national population-based case-control study. Clin Microbiol Infect. 2019; S1198-743X(19)30153-3.
   PubMed Web of Science ®Google Scholar
• Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis. 2003;9(11):1415–1422.
   PubMed Web of Science ®Google Scholar
• Owens Jr. RA, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for clostridium difficile infection. Clin Infect Dis. 2008;46:S19–31.
   PubMed Web of Science ®Google Scholar
• Palou J, Pigrau C, Molina I, et al. Etiology and sensitivity of uropathogens identified in uncomplicated lower urinary tract infections in women (ARESC Study): implications on empiric therapy. Med Clin (Barc) 2011;136(1):1–7.
   PubMed Web of Science ®Google Scholar
• Keepers TR, Gomez M, Celeri C, et al. Fosfomycin and comparator activity against select Enterobacteriaceae, Pseudomonas, and Enterococcus urinary tract infection isolates from the United States in 2012. Infect Dis Ther. 2017;6(2):233–243.
   PubMed Web of Science ®Google Scholar
• Wawrysiuk S, Naber K, Rechberger T, et al. Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance-non-antibiotic approaches: a systemic review. Arch Gynecol Obstet. 2019;300(4):821–828.
   PubMed Web of Science ®Google Scholar
• Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Front Microbiol. 2017;8:1566.
   PubMed Web of Science ®Google Scholar
• Asadi Karam MR, Habibi M, Bouzari S. Urinary tract infection: pathogenicity, antibiotic resistance and development of effective vaccines against uropathogenic Escherichia coli. Mol Immunol. 2019;108:56–67.
   PubMed Web of Science ®Google Scholar
• Buckner MMC, Ciusa ML, Piddock LJV. Strategies to combat antimicrobial resistance: anti-plasmid and plasmid curing. FEMS Microbiol Rev. 2018;42(6):781–804.
   PubMed Web of Science ®Google Scholar
• Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005; 365(9459):579–587.
   PubMed Web of Science ®Google Scholar
• Collignon PC, Conly JM, Andremont A, et al. World health organization ranking of antimicrobials according to their importance in human medicine: a critical step for developing risk management strategies to control antimicrobial resistance from food animal production. Clin Infect Dis. 2016;63:1087–1093.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global action plan on antimicrobial resistance. 2015 May. Free access. Available from http://www.who.int/drugresistance/global_action_plan/en/
   Google Scholar
• Noreikaite J, Jones P, Fitzpatrick J, et al. Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018;21(2):153–160.
   PubMed Web of Science ®Google Scholar
• Cussans A, Somani BK, Basarab A, et al. The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. BJU Int. 2016;117(5):725–731.
   PubMed Web of Science ®Google Scholar